Indication and Limitation of Use

Vectibix® is indicated for the treatment of patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC): as first-line therapy in combination with FOLFOX, and as… read more

Vectibix® is indicated for the treatment of patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for… read more

Vectibix® is indicated for the treatment of patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC): as first-line therapy in… read more

Vectibix® is indicated for the treatment of patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC): as first-line therapy in combination with FOLFOX, and as monotherapy following disease progression after prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy.

Vectibix® is not indicated for the treatment of patients with RAS-mutant mCRC or for whom RAS mutation status is unknown.

×
×

You are now leaving Vectibix.com

Please know that the sponsors of this site are not responsible for content on the site you are about to enter.

Cancel
Continue

 

Spot the difference

Choose Vectibix®

MEET A HYPOTHETICAL PATIENT WITH FIRST-LINE mCRC MEET A HYPOTHETICAL PATIENT WITH THIRD-LINE mCRC

*Defined as wild type in both KRAS and NRAS.1

These case studies are hypothetical examples and do not represent actual patients.

mCRC = metastatic colorectal cancer; WT = wild type.


<
>
Site Map
×